Processing your request

please wait...

Case Page


Case Status:    ONGOING  
—On or around 06/12/2024 (Date of last review)
Current/Last Presiding Judge:  
Hon. David A. Ezra

Filing Date: February 02, 2024

According to the Complaint, Cassava Sciences, Inc. is a clinical-stage biotechnology company. The Company’s lead therapeutic drug candidate is simufilam, a small molecule drug for the proposed treatment of Alzheimer’s disease.

The Complaint alleges that, throughout the Class Period, Defendants made materially false and/or misleading statements and failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, the Complaint alleges Defendants made false and/or misleading statements and/or failed to disclose that: (i) the Company failed to maintain adequate and effective data management controls and procedures related to its drug research programs; (ii) as a result, the data published in support of simufilam were susceptible to manipulation to overstate the drug's effectiveness; (iii) accordingly, Cassava had misrepresented the efficacy of its research programs and the clinical and/or commercial prospects of simufilam; (iv) all of the foregoing, once revealed, was likely to subject the Company to significant financial and/or reputational harm; and (v) as a result, the Company's public statements were materially false and misleading at all relevant times.

On May 28, 2024, the Court issued an Order transferring the case to the U.S. District Court for the Western District of Texas. The case transferred in under Docket 24-CV-00590.

Protected Content

Please Log In or Sign Up for a free account to access restricted features of the Clearinghouse website, including the Advanced Search form and the full case pages.

When you sign up, you will have the option to save your search queries performed on the Advanced Search form.